Europe’s next act & the Porter report: a BioCentury podcast
With the U.K.’s split from the EU in the rearview mirror, what are the new opportunities for each side? On the latest BioCentury This Week podcast, BioCentury’s editors are joined by Executive Director Josh Berlin, who previews BioCentury’s upcoming Bio€quity Europe conference. They also discuss Rep. Katie Porter’s report on pharma M&A and the latest in the FDA commissioner selection process.
Berlin previews the themes that the May 17-19 Bio€quity meeting — the conference’s 21st incarnation — will address: Where is biopharma innovation headed in Europe? What innovation are investors funding? What are Europe’s top partnering deals? How will the U.K. split with the EU work for both parties?
Berlin also describes how the meeting’s virtual setting creates the opportunity for BioCentury to expand the conference to include more companies from around the globe, in particular from China and South Korea.
U.K.-based Associate Editor Stephen Hansen highlights the record venture funds European VCs are raising, which he expects to translate into a robust fund-raising environment for the region’s early-stage innovators. On the M&A front, Hansen pointed to French pharma Servier as a company remaking itself into an innovative cancer company via a spate of deals to bring in innovative assets and bolster its R&D team. The company is now on the cusp of being a major player in oncology, he says.